{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:01Z","timestamp":1772165701341,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Predictors of major adverse kidney events (MAKE) in focal segmental glomerulosclerosis (FSGS) have not been previously explored within large, real-world populations. The study aim was to evaluate population-level predictors of MAKE attributed to FSGS from health system data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study population was derived from electronic health records from Providence and University of California Los Angeles Health Systems. Identification of FSGS was based on International Classification of Diseases 9\/10 diagnostic codes. Cox proportional hazards models were used to estimate the effects of traditional clinical and unique non-traditional variables including age, gender, race and ethnicity, health system, health insurance, healthcare utilization, estimated glomerular filtration rate (eGFR), diabetes, hypertension, and prescription medications as predictors of MAKE defined as:\u2009\u2265\u200940% eGFR decline, kidney failure (eGFR\u2009&lt;\u200915\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      , administrative codes for kidney failure, dialysis, or transplant) and death.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Adults with FSGS (N\u2009=\u2009629) were 54% (n\u2009=\u2009342) men and 53\u2009\u00b1\u200917 (mean\u2009\u00b1\u2009SD) years old. Baseline eGFR was 60\u2009\u00b1\u200930\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      , while median (interquartile range) urine albumin\/creatinine ratio (UACR) and urine protein\/creatinine ratio (UPCR) were 1,430 (520\u20132,630) mg\/g and 1.6 (0.5\u20133.9) g\/g, respectively. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers were prescribed to 76% (n\u2009=\u2009475), while corticosteroids and other immunomodulators were prescribed in 47% (n\u2009=\u2009297) and 12% (n\u2009=\u200974), respectively. MAKE were observed in 42% (n\u2009=\u2009262) of study participants over a median of 2.9 (1.4\u20134.5) years. Higher hazard for MAKE was associated with baseline above-median UACR or UPCR (HR [95% CI] (3.46 [2.28\u20135.23]) in patients with available measures, prescription for non-corticosteroid immunomodulator (1.87 [1.32\u20132.65]), non-commercial health insurance (1.78 [1.36\u20132.33]), hospitalization (1.64 [1.25\u20132.15]), lower eGFR per 10\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      1.25 [1.18\u20131.32]), number of outpatient visits (1.03 [1.01\u20131.05]) and lower hazard for MAKE was associated with older age (0.89 [0.82\u20130.98]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Substantial loss of kidney function or kidney failure occurred in more than four in ten patients with FSGS by a median of three years. MAKE were predicted by unique population level factors, such as healthcare utilization and insurance type, which may help to identify patients with FSGS, who could most benefit from diagnostic testing and interventions to improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04334-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T12:12:25Z","timestamp":1752927145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population risk predictors of major adverse kidney events attributed to focal segmental glomerulosclerosis from the CURE-CKD registry"],"prefix":"10.1186","volume":"26","author":[{"given":"Susanne B.","family":"Nicholas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey M.","family":"Kornowske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cami R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenn B.","family":"Daratha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radica Z.","family":"Alicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith C.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"3","key":"4334_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2215\/CJN.05960616","volume":"12","author":"AZ Rosenberg","year":"2017","unstructured":"Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2017;12(3):502\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4334_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ajmg.c.31990","volume":"190","author":"M Sambharia","year":"2022","unstructured":"Sambharia M, Rastogi P, Thomas CP. Monogenic focal segmental glomerulosclerosis: a conceptual framework for identification and management of a heterogeneous disease. Am J Med Genet C Semin Med Genet 2022;190(3):377\u201398.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"4334_CR3","doi-asserted-by":"crossref","unstructured":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100(4s):S1-s276.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"4","key":"4334_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","volume":"25","author":"JJ Rydel","year":"1995","unstructured":"Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25(4):534\u201342.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"4334_CR5","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.mayocp.2017.09.011","volume":"92","author":"MS Hommos","year":"2017","unstructured":"Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, Bharucha K, Lepori N, Rule AD, Fervenza FC. The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study. Mayo Clin Proc 2017;92(12):1772\u201381.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"4334_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ndt\/gfx189","volume":"33","author":"MM O\u2019Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant 2018;33(4):661\u201369.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"4334_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 2021;100(4):753\u201379.","journal-title":"Kidney Int"},{"issue":"8","key":"4334_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","volume":"15","author":"MJ Chun","year":"2004","unstructured":"Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169\u201377.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4334_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0272-6386(96)90098-0","volume":"27","author":"SM Korbet","year":"1996","unstructured":"Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27(5):647\u201351.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"4334_CR10","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.2215\/CJN.13091215","volume":"11","author":"LP Laurin","year":"2016","unstructured":"Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, et al. Renal survival in patients with collapsing compared with not otherwise specified FSGS. Clin J Am Soc Nephrol 2016;11(10):1752\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4334_CR11","doi-asserted-by":"crossref","unstructured":"Stamellou E, Nadal J, Hendry B, Mercer A, Bechtel-Walz W, Schiffer M, Eckardt KU, Kramann R, Moeller MJ, Floege J. Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort. Clin Kidney J 2024;17(7):sfae131.","DOI":"10.1093\/ckj\/sfae131"},{"issue":"3","key":"4334_CR12","first-page":"115","volume":"33","author":"M Wehrmann","year":"1990","unstructured":"Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33(3):115\u201322.","journal-title":"Clin Nephrol"},{"issue":"1","key":"4334_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.34067\/KID.0006172020","volume":"2","author":"BM Forster","year":"2021","unstructured":"Forster BM, Nee R, Little DJ, Greasley PJ, Hughes JB, Gordon SM, Olson SW. Focal segmental glomerulosclerosis, risk factors for end stage kidney disease, and response to immunosuppression. Kidney360 2021;2(1):105\u201313.","journal-title":"Kidney360"},{"issue":"12","key":"4334_CR14","doi-asserted-by":"publisher","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, McPherson SM, Neumiller JJ, Bell DS, Mangione CM, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the cure-ckd registry. JAMA Network Open 2019;2(12):e1918169.","journal-title":"JAMA Network Open"},{"issue":"1","key":"4334_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12882-019-1558-9","volume":"20","author":"KC Norris","year":"2019","unstructured":"Norris KC, Duru OK, Alicic RZ, Daratha KB, Nicholas SB, McPherson SM, Bell DS, Shen JI, Jones CR, Moin T, et al. Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD. BMC Nephrol 2019;20(1):416.","journal-title":"BMC Nephrol"},{"issue":"19","key":"4334_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, et al. New creatinine- and cystatin c-based equations to estimate gfr without race. N Engl J Med 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"key":"4334_CR17","unstructured":"SSA\u2019s death information, https:\/\/www.ssa.gov\/dataexchange\/request_dmf.html"},{"key":"4334_CR18","unstructured":"Statewide death profiles, https:\/\/data.chhs.ca.gov\/dataset\/statewide-death-profiles"},{"key":"4334_CR19","unstructured":"R core team: a language and environment for statistical computing. https:\/\/www.R-project.org\/ Accessed 6\/21\/2022.In R Foundation for Statistical Computing."},{"key":"4334_CR20","unstructured":"Therneau T AE, Crowson C. A package for survival analysis in R_. R package version 3.3-1. https:\/\/github.com\/therneau\/survival. Acessed 6\/21\/2023."},{"key":"4334_CR21","unstructured":"TA G: _prodlim: product-limit estimation for censored event history analysis_. R package version 2023.03.31. https:\/\/CRAN.R-project.org\/package=prodlim."},{"key":"4334_CR22","unstructured":"What\u2019s the difference between medicare and medicaid? Accessed 10\/2\/2024. https:\/\/www.hhs.gov\/answers\/medicare-and-medicaid\/what-is-the-difference-between-medicare-medicaid\/index.html"},{"issue":"2","key":"4334_CR23","doi-asserted-by":"publisher","first-page":"100748","DOI":"10.1016\/j.xkme.2023.100748","volume":"6","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Abner CW, Walker PD, Wang K, Rava A, Heo J, Bunke M. Clinical characteristics and histopathology in adults with focal segmental glomerulosclerosis. Kidney Med 2024;6(2):100748.","journal-title":"Kidney Med"},{"issue":"12","key":"4334_CR24","doi-asserted-by":"publisher","first-page":"e0315302","DOI":"10.1371\/journal.pone.0315302","volume":"19","author":"D Goldschmidt","year":"2024","unstructured":"Goldschmidt D, Bensink ME, Zhou ZY, Shi S, Lin Y, Shi L. Epidemiology and burden of focal segmental glomerulosclerosis among United States Veterans: an analysis of Veteran\u2019s Affairs data;PLoS One 2024;19(12):e0315302.","journal-title":"PLoS One"},{"issue":"4","key":"4334_CR25","doi-asserted-by":"publisher","first-page":"e012674","DOI":"10.1136\/bmjopen-2016-012674","volume":"7","author":"P Whiting","year":"2017","unstructured":"Whiting P, Morden A, Tomlinson LA, Caskey F, Blakeman T, Tomson C, Stone T, Richards A, Savovi\u0107J, Horwood J. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open 2017;7(4):e012674.","journal-title":"BMJ Open"},{"key":"4334_CR26","doi-asserted-by":"crossref","unstructured":"Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open 2016;6(12):e012690.","DOI":"10.1136\/bmjopen-2016-012690"},{"issue":"4","key":"4334_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2215\/CJN.14021118","volume":"14","author":"C Tomson","year":"2019","unstructured":"Tomson C, Tomlinson LA. Stopping ras inhibitors to minimize aki: more harm than good? Clin J Am Soc Nephrol 2019;14(4):617\u201319.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4334_CR28","doi-asserted-by":"publisher","first-page":"1464689","DOI":"10.3389\/fphar.2024.1464689","volume":"15","author":"M Wawruch","year":"2024","unstructured":"Wawruch M, Petrova M, Celovska D, Alfian SD, Tesar T, Murin J, Trnka M, Paduch T, Aarnio E. Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients. Front Pharmacol 2024;15:1464689.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4334_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/03007995.2021.1872515","volume":"37","author":"JB Rice","year":"2021","unstructured":"Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome. Curr Med Res Opin 2021;37(3):431\u201341.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"4334_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","volume":"77","author":"JP Troost","year":"2021","unstructured":"Troost JP, Trachtman H, Spino C, Kaskel FJ, Friedman A, Moxey-Mims MM, Fine RN, Gassman JJ, Kopp JB, Walsh L, et al. Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis. Am J Kidney Dis 2021;77(2):216\u201325.","journal-title":"Am J Kidney Dis"},{"key":"4334_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fmed.2018.00098","volume":"5","author":"Y Wen","year":"2018","unstructured":"Wen Y, Shah S, Campbell KN. Molecular mechanisms of proteinuria in focal segmental glomerulosclerosis. Front Med Lausanne 2018;5:98.","journal-title":"Front Med Lausanne"},{"issue":"10","key":"4334_CR32","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1681\/ASN.2005010055","volume":"16","author":"BL Wharram","year":"2005","unstructured":"Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005;16(10):2941\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"4334_CR33","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1681\/ASN.2021101396","volume":"33","author":"J Zee","year":"2022","unstructured":"Zee J, Liu Q, Smith AR, Hodgin JB, Rosenberg A, Gillespie BW, Holzman LB, Barisoni L, Mariani LH. Kidney biopsy features most predictive of clinical outcomes in the spectrum of minimal change disease and focal segmental glomerulosclerosis. J Am Soc Nephrol 2022;33(7):1411\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4334_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2215\/CJN.06100612","volume":"8","author":"VD D\u2019Agati","year":"2013","unstructured":"D\u2019Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, Cohen AH, Gipson DS, Gassman JJ, Radeva MK, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013;8(3):399\u2013406.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4334_CR35","first-page":"362","volume":"46","author":"H Shiiki","year":"1996","unstructured":"Shiiki H, Nishino T, Uyama H, Kimura T, Nishimoto K, Iwano M, Kanauchi M, Fujii Y, Dohi K. Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis (FSGS). Clin Nephrol 1996;46(6):362\u201368.","journal-title":"Clin Nephrol"},{"issue":"6","key":"4334_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ckj\/sfu100","volume":"7","author":"S Sethi","year":"2014","unstructured":"Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin Kidney J 2014;7(6):531\u201337.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4334_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12882-019-1498-4","volume":"20","author":"HG He","year":"2019","unstructured":"He HG, Wu CQ, Ye K, Zeng C, Huang YY, Luo SW, Yin W, Ye QR, Peng XM. Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases. BMC Nephrol 2019;20(1):328.","journal-title":"BMC Nephrol"},{"issue":"3","key":"4334_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ndt\/14.suppl_3.68","volume":"14","author":"SM Korbet","year":"1999","unstructured":"Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 1999;14 Suppl 3:68\u201373.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"4334_CR39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/nep.12816","volume":"22","author":"AM Greenwood","year":"2017","unstructured":"Greenwood AM, Gunnarsson R, Neuen BL, Oliver K, Green SJ, Baer RA. Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in far north queensland australian adults. Nephrology (Carlton) 2017;22(7):520\u201330.","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"4334_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.34067\/KID.0003552020","volume":"2","author":"AH Flannery","year":"2021","unstructured":"Flannery AH, Bosler K, Ortiz-Soriano VM, Gianella F, Prado V, Lambert J, Toto RD, Moe OW, Neyra JA. Kidney biomarkers and major adverse kidney events in critically ill patients. Kidney360 2021;2(1):26\u201332.","journal-title":"Kidney360"},{"issue":"7","key":"4334_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10916-016-0528-z","volume":"40","author":"MW Semler","year":"2016","unstructured":"Semler MW, Rice TW, Shaw AD, Siew ED, Self WH, Kumar AB, Byrne DW, Ehrenfeld JM, Wanderer JP. Identification of major adverse kidney events within the electronic health record. J Med Syst 2016;40(7):167.","journal-title":"J Med Syst"},{"issue":"1","key":"4334_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9(1):22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"4334_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000529773","volume":"9","author":"Y Cai","year":"2023","unstructured":"Cai Y, Liu Y, Tong J, Jin Y, Liu J, Hao X, Ji Y, Ma J, Pan X, Chen N, et al. Develop and validate a risk score in predicting renal failure in focal segmental glomerulosclerosis. Kidney Dis (Basel) 2023;9(4):285\u201397.","journal-title":"Kidney Dis (Basel)"},{"issue":"6","key":"4334_CR44","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1038\/sj.ki.4491164","volume":"56","author":"VC Chitalia","year":"1999","unstructured":"Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999;56(6):2236\u201342.","journal-title":"Kidney Int"},{"issue":"6","key":"4334_CR45","first-page":"408","volume":"15","author":"S Ossareh","year":"2021","unstructured":"Ossareh S, Yahyaei M, Asgari M, Bagherzadegan H, Afghahi H. Kidney outcome in primary focal segmental glomerulosclerosis (FSGS) by using a predictive model. Iran J Kidney Dis 2021;15(6):408\u201318.","journal-title":"Iran J Kidney Dis"},{"key":"4334_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12014-020-09282-x","volume":"17","author":"Q Weng","year":"2020","unstructured":"Weng Q, Zhou Q, Tong J, Jin Y, Liu Y, Yu X, Pan X, Ren H, Wang W, Xie J, et al. New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease. Clin Proteomics 2020;17:18.","journal-title":"Clin Proteomics"},{"issue":"12","key":"4334_CR47","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1007\/s11255-022-03254-w","volume":"54","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Xu W, Wan C, Chen Y, Zhang C. Prediction model for the risk of ESKD in patients with primary FSGS. Int Urol Nephrol 2022;54(12):3211\u201319.","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"4334_CR48","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018;29(11):2745\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4334_CR49","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1097\/TP.0000000000004985","volume":"108","author":"J Shoji","year":"2024","unstructured":"Shoji J, Goggins WC, Wellen JR, Cunningham PN, Johnston O, Chang SS, Solez K, Santos V, Larson TJ, Takeuchi M, et al. Efficacy and safety of bleselumab in preventing the recurrence of primary focal segmental glomerulosclerosis in kidney transplant recipients: a phase 2a, randomized, multicenter study. Transplantation 2024;108(8):1782\u201392.","journal-title":"Transplantation"},{"issue":"9","key":"4334_CR50","doi-asserted-by":"publisher","first-page":"e0136558","DOI":"10.1371\/journal.pone.0136558","volume":"10","author":"JM Thurman","year":"2015","unstructured":"Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS One 2015;10(9):e0136558.","journal-title":"PLoS One"},{"issue":"12","key":"4334_CR51","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.2012030302","volume":"23","author":"C Wei","year":"2012","unstructured":"Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012;23(12):2051\u201359.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4334_CR52","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1681\/ASN.2017090958","volume":"29","author":"AS De Vriese","year":"2018","unstructured":"De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating primary, genetic, and secondary fsgs in adults: a clinicopathologic approach. J Am Soc Nephrol 2018;29(3):759\u201374.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4334_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1053\/j.akdh.2024.03.009","volume":"31","author":"V Suresh","year":"2024","unstructured":"Suresh V, Stillman IE, Campbell KN, Meliambro K. Focal segmental glomerulosclerosis. Adv Kidney Dis Health 2024;31(4):275\u201389.","journal-title":"Adv Kidney Dis Health"},{"key":"4334_CR54","doi-asserted-by":"crossref","unstructured":"Catanese L, Siwy J, Wendt R, Amann K, Beige J, Hendry B, Mischak H, Mullen W, Paterson I, Schiffer M, et al. Differentiating primary and secondary FSGS using non-invasive urine biomarkers. Clin Kidney J 2024;17(2):sfad296.","DOI":"10.1093\/ckj\/sfad296"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04334-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04334-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04334-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:47:25Z","timestamp":1757260045000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04334-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04334-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5844460\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the Providence and University of California Los Angeles Health Institutional Review Boards, who determined written informed consent was not required for analyses of a retrospective, limited dataset, and was conducted according to Reporting of Observational Studies in Epidemiology guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SBN is supported by NIH research grants R01MD014712, RF00250-2022-0038, U2CDK129496 and P50MD017366, CDC project number 75D301-21-P-12254, and the Terasaki Institute of Biomedical Innovation; receives research support from Travere Therapeutics Inc. for the submitted work; and personal fees and other support from AstraZeneca, Bayer AG, Gilead, Novo Nordisk and Boehringer Ingelheim\/Lilly. LMK is supported by an NIH research grant OT2OD032581 and CDC project number 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from Travere Therapeutics Inc. for the submitted work, and Benaroya Research Institute outside of the submitted work. CRJ is supported by an NIH research grant R01MD014712, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from the Doris Duke Charitable Foundation and Benaroya Research Institute outside of the submitted work, and Travere Therapeutics Inc. for the submitted work. KBD is supported by NIH research grants R01MD014712, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from the Doris Duke Charitable Foundation and Benaroya Research Institute outside of the submitted work, and Travere Therapeutics Inc. for the submitted work. RZA is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from Travere Therapeutics Inc. for the submitted work, the Doris Duke Charitable Foundation, Benaroya Research Institute Bayer AG, AstraZeneca, The George Institute for Global Health, CareDx, and KBP BioSceinces outside the submitted work, and personal fees from Boehringer Ingelheim; Bayer Pharmaceuticals, and Eli Lilly. CLR is supported by NIH research grants OT2OD032581 and reports other support from the Doris Duke Charitable Foundation and Benaroya Research Institute outside the submitted work, and Travere Therapeutics Inc for the submitted work. JJN is supported by NIH research grant OT2OD032581 and a research grant from the American College of Clinical Pharmacy, and reports personal fees and other support from Bayer AG, Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Proteomics International, and Dexcom outside the submitted work. MEB is an employee of Benefit Consulting PTY LTD, Brisbane, Australia and has received consulting fees from Travere Therapeutics, Inc. and Amgen, Inc. WG is an employee of Travere Therapeutics Inc. KCN is supported in part by NIH research grants UL1TR001881, P30AG021684, U2CDK129496 and P50MD017366, and reports personal fess from Atlantis Dialysis Inc. and AstraZeneca. KRT is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, OT2OD032581, and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264. She has also received investigator-initiated grant support from Travere Therapeutics, Inc. for the submitted work and from Bayer Pharmaceuticals, the Doris Duke Charitable Foundation, and Benaroya Research Institute outside of the submitted work. She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Pfizer; and speaker fees from Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}